Table 2.
Clinical characteristics of patients in the training and validation set.
| Characteristics | Training | Validation | P |
|---|---|---|---|
| (N = 91) | (N = 46) | ||
| Gender | 0.54 | ||
| Male | 53 | 30 | |
| Female | 38 | 16 | |
| Age | 0.90 | ||
| <60 | 49 | 26 | |
| ≥60 | 42 | 20 | |
| BMI | 0.64 | ||
| <18.5 | 8 | 6 | |
| 18.5-24 | 56 | 25 | |
| >24 | 27 | 15 | |
| Smoking | 0.28 | ||
| no | 74 | 33 | |
| yes | 17 | 13 | |
| Family history | 0.85 | ||
| no | 72 | 35 | |
| yes | 19 | 11 | |
| HB (g/l) | 0.78 | ||
| <120 | 15 | 6 | |
| ≥120 | 76 | 40 | |
| CEA (ng/ml) | 0.99 | ||
| <5 | 56 | 28 | |
| ≥5 | 35 | 18 | |
| CA19-9 (u/ml) | 0.53 | ||
| <35 | 82 | 39 | |
| ≥35 | 9 | 7 | |
| T stage | 0.42 | ||
| T3a | 28 | 13 | |
| T3b | 24 | 16 | |
| T3c | 4 | 0 | |
| T4a | 35 | 17 | |
| Distance (cm) | 0.55 | ||
| ≤5 | 14 | 8 | |
| 5.1-10 | 65 | 29 | |
| >10 | 12 | 9 | |
| TIC | 0.69 | ||
| 1/4 | 1 | 1 | |
| 2/4 | 26 | 11 | |
| 3/4 | 41 | 25 | |
| 4/4 | 23 | 9 | |
| MRF | 0.64 | ||
| negative | 77 | 32 | |
| positive | 14 | 14 | |
| EMVI | 0.45 | ||
| negative | 72 | 32 | |
| positive | 19 | 14 | |
| LN metastasis | 0.20 | ||
| negative | 63 | 26 | |
| positive | 28 | 20 | |
| max LN (mm) | 0.04* | ||
| <5 | 48 | 15 | |
| ≥5 | 43 | 31 | |
| TRG | 0.83 | ||
| 0 | 76 | 37 | |
| 1 | 15 | 9 |
*p < 0.05.